GeoVax to Showcase Vaccine and Cancer Therapy Progress at Emerging Growth Conference
GeoVax Labs, Inc. will present updates on its GEO-MVA, GEO-CM04S1, and Gedeptin® programs at the Emerging Growth Conference, highlighting advancements in vaccine development and cancer therapy.
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on July 16, 2025. The presentation will focus on the company's progress in developing vaccines and immunotherapies for infectious diseases and cancer, including updates on GEO-MVA, GEO-CM04S1, and Gedeptin® programs.
David Dodd, Chairman and CEO of GeoVax, will discuss the company's pipeline, highlighting the GEO-MVA vaccine's recent favorable Scientific Advice from the European Medicines Agency, the ongoing Phase 2 clinical trials for GEO-CM04S1, and the upcoming Phase 2 trial for Gedeptin® in head and neck cancer. The presentation will also cover GeoVax's manufacturing capabilities and its role in addressing vaccine supply diversification and pandemic readiness.
Interested parties can register to attend the conference here. Questions can be submitted in advance or during the live Q&A session, with a replay available post-event on the Emerging Growth website and YouTube channel.